. . "You can do lots more research as a company than as many biotechs - you have the infrastructure and experience in particular areas that no small biotech is likely to have, and the so the money you spend on internal R+D goes to R+D, not building up the same (or rather, smaller and less effective versions) infrastructure lots of times." . . .